(Q42985641)

12 November 2017

title

Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer (English)

1 reference

12 November 2017

Xin An

1

1 reference

12 November 2017

Pei-Rong Ding

2

1 reference

12 November 2017

Yu-Hong Li

3

1 reference

12 November 2017

Feng-Hua Wang

4

1 reference

12 November 2017

Yan-Xia Shi

5

1 reference

12 November 2017

Zhi-Qiang Wang

6

1 reference

12 November 2017

You-Jian He

7

1 reference

12 November 2017

Rui-Hua Xu

8

1 reference

12 November 2017

Wen-Qi Jiang

9

1 reference

12 November 2017

publication date

1 September 2010

1 reference

12 November 2017

1 reference

12 November 2017

volume

15

1 reference

12 November 2017

issue

6

1 reference

12 November 2017

page(s)

516-522

1 reference

Gemcitabine combined with oxaliplatin is safe and effective in patients with previously untreated advanced pancreatic adenocarcinoma.

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Inflammation and cancer: back to Virchow?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Prognostic factors in the palliation of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Metastatic pancreatic cancer 2008: is the glass less empty?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1354750X.2010.491557

10.3109/1354750X.2010.491557

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference